For most of its life on the public market, ECO Animal Health Group has been synonymous with a single molecule. Its financial results published on 15 July 2026 suggest a company trying to become something broader: a diversified livestock-health business built around vaccines and next-generation therapeutics as well as its long-established antibiotic.

The Quick Version

  • ECO derives most revenue from Aivlosin, a proprietary tylvalosin macrolide antibiotic for pigs and poultry sold in more than 70 markets.
  • FY2026 (year to 31 March 2026) revenue rose 10% to £87.5m, gross margin improved to 48.6%, adjusted EBITDA was £8.5m; the group held £25.4m net cash and recommended no dividend.
  • The company is diversifying into vaccines, launching its ECOVAXXIN MS poultry vaccine in July 2026 and targeting up to nine US or EU approvals over five to six years.
  • China remains a material market and a swing factor; weaker pork prices dampened late-year demand, while North America and Latin America drove growth.
  • The investment case turns on execution of the pipeline, defending Aivlosin against generic competition, and navigating cyclical livestock economics.

What ECO Actually Does

ECO is a veterinary pharmaceuticals business focused on medicines for pigs and poultry, listed on AIM under EAH. Its defining asset is Aivlosin (also Valosin), a proprietary, patented macrolide antibiotic effective against respiratory and enteric bacterial diseases, particularly mycoplasma infections — distributed across more than 70 markets. It also sells generic products under Ecomectin and Ecotraz.

The Antimicrobial Resistance Backdrop

ECO sits between two forces: rising global demand for animal protein and intensifying scrutiny of antibiotic use in farming. Regulators in Europe, North America and Asia have restricted routine, preventative antibiotic use, encouraging targeted therapeutic use and alternatives such as vaccines. ECO's broadening into vaccines is an explicit response to that shift, aiming to align the portfolio with where regulators and producers are heading.

ECOVAXXIN MS: The First Commercial Step Beyond Aivlosin

ECOVAXXIN MS, a vaccine against Mycoplasma synoviae in poultry, received EU marketing approval in December 2025 and launched commercially in July 2026 with first orders received, carrying a claimed 44-week duration of immunity. A US Department of Agriculture approval is expected by end-2026, with dossiers also filed in Thailand and Argentina. Behind it sits ECOVAXXIN MG (a second poultry vaccine), a PCV2/Mhyo bivalent swine vaccine, a PRRS monoclonal antibody, and a long-acting florfenicol treatment. Management expects up to nine products to secure US or EU approval over five to six years — an ambition, not a guarantee.

The Numbers

FY2026 revenue was £87.5m, up 10% (14% at constant currency — £91.0m — indicating sterling strength masked stronger underlying growth). Gross margin improved to 48.6% from 45.1%. Adjusted EBITDA rose 16% to £8.5m (9.8% margin), profit before tax increased 35% to £5.4m, and EPS reached 3.26p from 2.49p. Net cash stood at £25.4m, with 61% held outside China. No dividend was recommended; total R&D was £8.8m, about 10% of revenue.

By region: North America contributed £26.1m (up 22%), China and Japan £24.1m (up 5%), Latin America £18.8m (up 15%), South and Southeast Asia £11.1m (down 7%).

Why the Pipeline Matters

As Aivlosin matures, defending it against generic competition is an ongoing investment priority. Vaccines and novel therapeutics are, in part, a strategic answer: harder-to-replicate products that reduce dependence on a single molecule. Whether ECO can carve defensible niches against larger incumbents in vaccines remains to be demonstrated.

Risks Worth Weighing

Concentration is the most obvious risk — Aivlosin remains the dominant revenue driver, and any acceleration of generic competition or regulatory change affecting antibiotics in agriculture could weigh materially. Cyclicality is a second: livestock economics directly influence spending on animal health, as the FY2026 China commentary illustrated (reported losses of up to $60 per farmed pig). Pipeline execution carries its own uncertainty — approvals can slip or fail, and new-vaccine economics are unproven at scale for ECO.

What to Watch Next

USDA approval of ECOVAXXIN MS, expected by end-2026. Additional international registrations in Thailand and Argentina. Progress on the swine pipeline, including targeted 2028 approvals. A recovery in Chinese pork economics and normal second-half seasonal weighting for FY2027.